Sensus Healthcare inks multiple distro deals, launches global expansion project

Superficial radiation therapy device developer Sensus Healthcare (NSDQ:SRTSU) today released plans for a global expansion, including new distribution agreements in China, Germany, Mexico, Cuba and Costa Rica. Sensus makes low-energy photon X-ray systems for treating non-melanoma skin cancers, including basal cell and squamous cell carcinomas, and keloids. The Boca Raton, Fla.-based company refers to the technology as superficial radiation therapy, and claims that the tech has been sued to “effectively and safely treat oncological and non-oncological skin conditions.” “Following our new partnership with Cellmark, the opening of our Tel Aviv office earlier this year, as well as Sensus’ SRT-100 keloid treatment launch in China and market clearance in Mexico in late 2017, the Company’s international efforts are moving full steam ahead in 2018, and our executive team is shifting to meet this growing demand for SRT. Not only are we reaching new patients in these markets who want a less-invasive way to treat non-melanoma skin cancer and keloids without surgery for a better quality of life, we’re also continuing to build relationships with innovative minds in several booming aesthetic markets, due to the recent launch of our new Sensus Laser Systems. This is the time to watch Sensus, as we are uniquely positioned to offer a range of solutions to patients so that they look and feel their best from head to toe,...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Distribution Oncology Sensus Healthcare LLC Source Type: news

Related Links:

Authors: Feres M, Retamal-Valdes B, Faveri M, Duarte P, Shibli J, Soares GMS, Miranda T, Teles F, Goodson M, Hasturk H, Van Dyke T, Ehmke B, Eickholz P, Schlagenhauf U, Meyle J, Koch R, Kocher T, Hoffmann T, Kim TS, Kaner D, Figueiredo LC, Doyle H Abstract OBJECTIVE: The selection of proper outcome measures is a critical step in clinical research. Most randomized clinical trials (RCTs) assessing the effects of initial anti-infective periodontal therapies use surrogate outcomes as primary outcome variables, such as mean changes in probing depth (PD) or in clinical attachment. However, these parameters do not reflect...
Source: Journal of the International Academy of Periodontology - Category: Dentistry Tags: J Int Acad Periodontol Source Type: research
Authors: Zhou S, Wei J, Wang Y, Liu X Abstract Hepatocellular carcinoma (HCC) is a leading cause of cancer-associated mortality worldwide. Despite clinical advances, the survival rate of patients with HCC remains low, as most patients are diagnosed with HCC when they are already at the advanced stage. Certain circular RNAs (circRNAs) are closely associated with the development of liver cancer. In the present study, a circRNA array was performed to screen differentially expressed circRNAs in HCC tissues. The further analysis focused on the newly identified circRNA_101237, the host gene of which, cyclin-dependent kin...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Authors: Li L, Zheng Y, Zheng Q, Jiang J Abstract The present study aimed to investigate the antiproliferative effect of embryonic stem cell-conditioned medium (ESC-CM) on the mouse liver cancer Hepa1-6 cells in vitro. Furthermore, in order to elucidate the underlying molecular mechanism, the microRNAs (miRNAs) in ESC-CM associated with the inhibition of Hepa1-6 proliferation were identified. Following the co-culture of ESC-CM and Hepa1-6 in Transwell chambers, the proliferation, cell cycle, apoptosis and associated protein expression were determined in Hepal-6 cells. Moreover, miRNA array analysis was employed to ...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
This article is licensed under aCreative Commons Attribution 3.0 Unported Licence.Chengfeng Bai, Rongfang Xue, Jianbing Wu, Tian Lv, Xiaojun Luo, Yun Huang, Yan Gong, Honghua Zhang, Yihua Zhang, Zhangjian Huang To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Chem. Commun. latest articles - Category: Chemistry Authors: Source Type: research
Trump says personal protective gear has nearly run out; Florida, Georgia, Mississippi ordered to shelter in place; record daily fatalities in UK. Follow the latest updates.At a glance: summary of key eventsWimbledon cancelled due to coronavirus crisisAustralia coronavirus – latest updatesSee all of our coronavirus coverage5.54amBSTThe Chinese city of Shenzhen has banned the eating of dogs and cats as part of a wider clampdown on the wildlife trade since the emergence of the new coronavirus, Reuters reports.Scientists suspect the coronavirus passed to humans from animals. Some of the earliest infections were found in ...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Coronavirus outbreak UK news World news Science Infectious diseases Middle East and North Africa South Africa Russia China Japan Asia Pacific Europe Medical research Microbiology Source Type: news
Bacteria in some tumors may hinder cancer treatments. (read more)
Source: Environmental Factor - NIEHS Newsletter - Category: Environmental Health Source Type: news
Publication date: Available online 1 April 2020Source: LinguaAuthor(s): Cai-Mei Yang, Tiao-Yuan Mao, Bing Bai
Source: Lingua - Category: Speech-Language Pathology Source Type: research
Sensus Healthcare is a medical device company that focuses on providing non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids utilizing superficial radiation technology (SRT). Their proprietary, FDA-cleared SRT technology...
Source: Medgadget - Category: Medical Devices Authors: Tags: Dermatology Exclusive Oncology Source Type: blogs
Sensus Healthcare (NSDQ:SRTSU) said today it closed its initial public offering, raising $11 million through the sale of 2.3 million units at $5.50 each. The offering included a fully-exercised underwriters option of an additional 300,000 units at the IPO price, Sensus said. Each share consists of a unit of stock and a 3-year warrant with an exercise price of $6.75. The offering units are slated to split by July 25, with the stock shares trading on the NASDAQ exchange under the “SRTS” symbol and the warrants under the “SRTSW” symbol. Sensus makes low-energy photon X-ray systems for treating non...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Funding Roundup Initial Public Offering (IPO) Radiosurgery Sensus Healthcare LLC Source Type: news
Sensus Healthcare (NSDQ:SRTSU) priced an $11 million initial public offering yesterday, saying it plans to float 2 million shares at $5.50 apiece starting today. Boca Raton, Fla.-based Sensus said the offering, expected to close June 8, also includes a 300,000-unit over-allotment option for the IPO’s underwriters. Each share consists of a unit of stock and a 3-year warrant with an exercise price of $6.75. The offering units are slated to split by July 25, with the stock shares trading on the NASDAQ exchange under the “SRTS” symbol and the warrants under the “SRTSW” symbol. Sensus mak...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Funding Roundup Initial Public Offering (IPO) Radiosurgery Wall Street Beat Sensus Healthcare LLC Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | China Health | Costa Rica Health | Cuba Health | Germany Health | Keloids | Laser Surgery | Medical Devices | Melanoma | Mexico Health | Nonmelanoma Skin Cancer | Partnerships | Radiation Therapy | Skin | Skin Cancer | Squamous Cell Carcinoma